M
Monopar Therapeutics D
D
MNPR
18.450
USD
-1.01
(-5.19%)
Market Closed
Volume
4,070
EPS
0
Div Yield
0
P/E
-8
Market Cap
64,950,753
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Monopar Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidiveforthe prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.